BiCAR Therapy - A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas after CAR T-cells therapy

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508301-25-00

Acronym

BiCAR Therapy

Enrollment

Registered

2023-11-23

Start date

2021-03-26

Completion date

2025-05-21

Last updated

2025-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapse/Refractory Lymphomas

Brief summary

Overall Survival (OS).

Detailed description

tolerability of glofitamab, Overall Metabolic Response Rate (OMRR), Best metabolic response and overall best metabolic response rate, Progression Free Survival (PFS), Duration of Response (DoR),, HRQoL)

Interventions

DRUGOBINUTUZUMAB

DRUGGLOFITAMAB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall Survival (OS).	—

Secondary

Measure	Time frame
tolerability of glofitamab, Overall Metabolic Response Rate (OMRR), Best metabolic response and overall best metabolic response rate, Progression Free Survival (PFS), Duration of Response (DoR),, HRQoL)	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026